AR035786A2 - Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen - Google Patents
Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienenInfo
- Publication number
- AR035786A2 AR035786A2 ARP020101003A ARP020101003A AR035786A2 AR 035786 A2 AR035786 A2 AR 035786A2 AR P020101003 A ARP020101003 A AR P020101003A AR P020101003 A ARP020101003 A AR P020101003A AR 035786 A2 AR035786 A2 AR 035786A2
- Authority
- AR
- Argentina
- Prior art keywords
- amino acid
- vitamin
- gla domain
- protein
- modified gla
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6464—Protein C (3.4.21.69)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se describen: polipéptidos dependientes de vitamina K que incluye un dominio GLA modificado que aumenta la afinidad de unión del polipéptido con las membranas con respecto al correspondiente polipéptido nativo dependiente de vitamina K. El dominio GLA modificado puede incluir por lo menos una sustitución de amino ácido. Por ejemplo, la sustitución de amino ácido puede ser en el amino ácido 11, 12, 29, 33 o 34. El dominio GLA modificado, puede incluir una secuencia de amino ácidos que, en el estado saturado de calcio, forma una estructura terciaria que tiene un núcleo catiónico con un halo de carga electro-negativa. El polipéptido dependiente de vitamina K, puede ser por ejemplo, proteína C, proteína C actividad, factor IX, factor IXa, factor VII, factor VIIa o factor VIIa de sitio activo modificado. El dominio GLA modificado de la proteína C o la proteína C activada puede incluir un residuo ácido glutámico en el amino ácido 33 y un residuo ácido aspártico en el amino ácido 34. El dominio GLA modificado de la proteína C o de la proteína C activada, puede también incluir un residuo glutamina o ácido glutámico en el amino ácido 11. Adicionalmente, un residuo glicina puede ser sustituido en el amino ácido 12 en el dominio GLA de la proteína C o de la proteína C activada. El dominio GLA modificado del factor VII, el factor VIIa y el factor VIIa de sitio activo modificado puede contener una sustitución en el amino ácido 11 y 33. Por ejemplo, un residuo glutamina en el amino ácido 11 y un residuo ácido glutámico en el amino ácido 33, pueden estar sustituidos. Un ácido nucleico aislado que codifica una polipéptido dependiente de vitamina K que contiene un dominio GLA modificado tal como se describe arriba. Además, la presente se refiere también a una célula hospedante de mamífero que incluye un vector ácido nucleico que codifica un polipéptido dependiente de vitamina K que contiene un dominio GLA modificado según se describe arriba. Una composición farmacéutica que incluye un vehículo farmacéuticamente aceptable y una cantidad de un polipéptido dependiente de vitamina K efectiva para inhibir o incrementar la formación de coágulos en un mamífero, donde el polipéptido dependiente de vitamina K incluye un dominio GLA modificado como se ha descripto anteriormente. Un polipéptido dependiente de la vitamina K para ser utilizado en el tratamiento de una trastorno relacionado con la coagulación o en la manufactura de un medicamento para el tratamiento de un trastorno de coagulación. Métodos para incrementar o disminuir la formación de coágulos en un mamífero.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/955,636 US6017882A (en) | 1997-10-23 | 1997-10-23 | Modified vitamin K-dependent polypeptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR035786A2 true AR035786A2 (es) | 2004-07-14 |
Family
ID=25497114
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980105278A AR020048A1 (es) | 1997-10-23 | 1998-10-22 | Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero. |
| ARP020101003A AR035786A2 (es) | 1997-10-23 | 2002-03-20 | Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP980105278A AR020048A1 (es) | 1997-10-23 | 1998-10-22 | Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero. |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6017882A (es) |
| EP (2) | EP1676919B1 (es) |
| JP (1) | JP4276379B2 (es) |
| KR (1) | KR20010031370A (es) |
| CN (1) | CN1246462C (es) |
| AP (1) | AP2000001811A0 (es) |
| AR (2) | AR020048A1 (es) |
| AT (1) | ATE390486T1 (es) |
| AU (1) | AU749279C (es) |
| BR (1) | BR9814611A (es) |
| CA (1) | CA2307175C (es) |
| DE (1) | DE69839313T2 (es) |
| DK (1) | DK1090128T3 (es) |
| EA (1) | EA200000449A1 (es) |
| ES (2) | ES2303362T3 (es) |
| HR (1) | HRP20000234A2 (es) |
| HU (1) | HU225993B1 (es) |
| ID (1) | ID26330A (es) |
| IL (1) | IL135603A0 (es) |
| IS (1) | IS5449A (es) |
| MY (1) | MY136336A (es) |
| NO (1) | NO20002025L (es) |
| NZ (1) | NZ504114A (es) |
| PL (1) | PL194194B1 (es) |
| PT (1) | PT1090128E (es) |
| SG (1) | SG105547A1 (es) |
| TR (1) | TR200001105T2 (es) |
| TW (1) | TW587081B (es) |
| WO (1) | WO1999020767A1 (es) |
| ZA (1) | ZA989597B (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6747003B1 (en) | 1997-10-23 | 2004-06-08 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7247708B2 (en) * | 1997-10-23 | 2007-07-24 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6693075B1 (en) * | 1997-10-23 | 2004-02-17 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US6998122B1 (en) | 1999-04-30 | 2006-02-14 | Eli Lilly And Company | Protein C derivatives |
| EP1237917A2 (en) * | 1999-11-19 | 2002-09-11 | Eli Lilly And Company | Protein c derivatives |
| CA2399267A1 (en) | 2000-02-02 | 2001-08-09 | Eli Lilly And Company | Protein c derivatives |
| DK1257295T3 (da) * | 2000-02-11 | 2009-08-10 | Bayer Healthcare Llc | Faktor VII eller VIIA-lignende molekyler |
| JP2003521938A (ja) | 2000-02-11 | 2003-07-22 | イーライ・リリー・アンド・カンパニー | プロテインｃ誘導体 |
| US7220837B1 (en) | 2000-04-28 | 2007-05-22 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US7812132B2 (en) * | 2000-04-28 | 2010-10-12 | Regents Of The University Of Minnesota | Modified vitamin K-dependent polypeptides |
| US20030211094A1 (en) * | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
| US7160540B2 (en) * | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
| US6423826B1 (en) | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
| AU7833601A (en) * | 2000-07-31 | 2002-02-13 | Daniel L Sparks | Charged lipid compositions and methods for their use |
| US6933367B2 (en) | 2000-10-18 | 2005-08-23 | Maxygen Aps | Protein C or activated protein C-like molecules |
| EP1370649A1 (en) * | 2001-03-02 | 2003-12-17 | T.A.C. Thrombosis and Coagulation AB | Protein c variants |
| JP2005518801A (ja) * | 2002-03-01 | 2005-06-30 | テイ・エイ・シー・スロムボシス・アンド・コアグラシヨン・アクテイエボラーク | 組換えプロテインｃバリアント |
| US20030186862A1 (en) * | 2002-04-02 | 2003-10-02 | Nelsestuen Gary L. | Factor VIIa compositions |
| PL373728A1 (en) * | 2002-04-30 | 2005-09-05 | Maxygen Holdings Ltd. | Factor vii or viia polypeptide variants |
| US20030232075A1 (en) * | 2002-05-06 | 2003-12-18 | University Of Minnesota, A Minnesota Corporation | Compositions for producing factor Xa |
| DK2283856T3 (da) | 2002-06-21 | 2017-11-20 | Novo Nordisk Healthcare Ag | Stabiliserede, faste sammensætninger af Faktor VIIa-polypeptider |
| US20040176704A1 (en) * | 2003-03-04 | 2004-09-09 | Stevens Timothy A | Collection device adapted to accept cartridge for point of care system |
| CN1780637A (zh) | 2003-03-18 | 2006-05-31 | 诺和诺德医疗保健公司 | 因子ⅶ多肽类的含水液体药物组合物 |
| DK1608745T3 (da) | 2003-03-20 | 2009-06-15 | Bayer Healthcare Llc | FVII eller FVIIa-Varianter |
| WO2004111242A1 (en) * | 2003-06-19 | 2004-12-23 | Maxygen Holdings Ltd. | FACTOR VII OR VIIa GLA DOMAIN VARIANTS |
| CN101870729A (zh) | 2003-09-09 | 2010-10-27 | 诺和诺德医疗保健公司 | 凝固因子ⅶ多肽 |
| KR100755967B1 (ko) * | 2003-10-23 | 2007-09-06 | 한국타이어 주식회사 | 타이어의 비드와 휠의 갭 측정장치 |
| AU2004294403A1 (en) | 2003-12-01 | 2005-06-16 | Novo Nordisk Health Care Ag | Nanofiltration of factor VII solutions to remove virus |
| ES2676644T3 (es) | 2003-12-19 | 2018-07-23 | Novo Nordisk Health Care Ag | Composiciones estabilizadas de polipéptidos de factor VII |
| CN103215328B (zh) | 2004-01-21 | 2016-08-03 | 诺和诺德医疗保健公司 | 转谷氨酰胺酶介导的肽的接合 |
| KR20130128013A (ko) | 2004-12-23 | 2013-11-25 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 관심있는 비타민 ｋ-의존성 단백질을 포함한 조성물 중의 단백질 오염물질의 양의 감소 |
| US8206750B2 (en) | 2005-03-24 | 2012-06-26 | Cerenis Therapeutics Holding S.A. | Charged lipoprotein complexes and their uses |
| EP1893230A2 (en) * | 2005-04-26 | 2008-03-05 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
| US8633300B2 (en) | 2005-06-17 | 2014-01-21 | Novo Nordisk Healthcare Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
| US7696318B2 (en) | 2005-07-13 | 2010-04-13 | Novo Nordisk Health Care Ag | Host cell protein knock-out cells for production of therapeutic proteins |
| WO2007026021A1 (en) | 2005-09-01 | 2007-03-08 | Novo Nordisk Health Care Ag | Hydrophobic interaction chromatography purification of factor vii polypeptides |
| WO2007031559A2 (en) | 2005-09-14 | 2007-03-22 | Novo Nordisk Health Care Ag | Human coagulation factor vii polypeptides |
| JP5570809B2 (ja) | 2006-09-01 | 2014-08-13 | ノボ ノルディスク ヘルス ケア アーゲー | 修飾タンパク質 |
| WO2008078189A2 (en) * | 2006-12-20 | 2008-07-03 | Bayer Healthcare Llc | Factor vii and viia compositions |
| BRPI0810172A2 (pt) | 2007-04-13 | 2014-10-14 | Catalyst Biosciences Inc | Polipeptídeos de fator vii modificado e seus usos |
| US20080305157A1 (en) * | 2007-06-08 | 2008-12-11 | University Of Maryland Office Of Technology Commercialization | Encapsulation and separation of charged organic solutes inside catanionic vesicles |
| DK2235197T3 (en) | 2007-12-27 | 2017-10-09 | Baxalta GmbH | Methods of cell culture |
| TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子ｖｉｉ多肽和其用途 |
| DK2440239T3 (en) | 2009-06-09 | 2017-10-16 | Prolong Pharmaceuticals Llc | HEMOGLOBIN FORMATIONS |
| US8809495B2 (en) * | 2009-12-14 | 2014-08-19 | National University Corporation Hokkaido University | Peptides imparting cell permeability to lipid membrane structure and/or enhancing cell permeability of lipid membrane structure, and lipid membrane structure comprising lipid bound to such peptide as constituent lipid and having cell permeability or showing enhanced cell permeability |
| TWI557135B (zh) | 2010-11-03 | 2016-11-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| ES2704083T3 (es) | 2012-07-25 | 2019-03-14 | Catalyst Biosciences Inc | Polipéptidos de factor x modificados y usos de los mismos |
| US11491212B1 (en) | 2017-09-27 | 2022-11-08 | Catalyst Biosciences, Inc. | Subcutaneous administration of modified factor IX polypeptides and treatment of hemophilia B |
| US20210069306A1 (en) | 2019-08-15 | 2021-03-11 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment |
| WO2021154414A2 (en) | 2020-01-29 | 2021-08-05 | Catalyst Biosciences, Inc. | Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0296413A2 (en) * | 1987-06-12 | 1988-12-28 | Hoechst Japan Limited | Hybrid protein C and method for its preparation |
| JPH0246296A (ja) * | 1988-08-09 | 1990-02-15 | Hoechst Japan Ltd | 雑種プロテインｃ及びその製造方法 |
| US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
| ATE180834T1 (de) * | 1990-01-29 | 1999-06-15 | Zymogenetics Inc | Antikoagulierende proteine |
| US5504064A (en) * | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
-
1997
- 1997-10-23 US US08/955,636 patent/US6017882A/en not_active Expired - Lifetime
-
1998
- 1998-10-20 ES ES98967009T patent/ES2303362T3/es not_active Expired - Lifetime
- 1998-10-20 DK DK98967009T patent/DK1090128T3/da active
- 1998-10-20 DE DE69839313T patent/DE69839313T2/de not_active Expired - Lifetime
- 1998-10-20 IL IL13560398A patent/IL135603A0/xx unknown
- 1998-10-20 PT PT98967009T patent/PT1090128E/pt unknown
- 1998-10-20 EA EA200000449A patent/EA200000449A1/ru unknown
- 1998-10-20 JP JP2000517087A patent/JP4276379B2/ja not_active Expired - Fee Related
- 1998-10-20 HU HU0102257A patent/HU225993B1/hu not_active IP Right Cessation
- 1998-10-20 ID IDW20000983A patent/ID26330A/id unknown
- 1998-10-20 CN CNB988125811A patent/CN1246462C/zh not_active Expired - Fee Related
- 1998-10-20 TW TW087117304A patent/TW587081B/zh active
- 1998-10-20 NZ NZ504114A patent/NZ504114A/xx unknown
- 1998-10-20 WO PCT/US1998/022152 patent/WO1999020767A1/en not_active Application Discontinuation
- 1998-10-20 EP EP05026205.4A patent/EP1676919B1/en not_active Expired - Lifetime
- 1998-10-20 KR KR1020007004378A patent/KR20010031370A/ko not_active Application Discontinuation
- 1998-10-20 TR TR2000/01105T patent/TR200001105T2/xx unknown
- 1998-10-20 AU AU27024/99A patent/AU749279C/en not_active Ceased
- 1998-10-20 EP EP98967009A patent/EP1090128B1/en not_active Expired - Lifetime
- 1998-10-20 AP APAP/P/2000/001811A patent/AP2000001811A0/en unknown
- 1998-10-20 BR BR9814611-4A patent/BR9814611A/pt active Search and Examination
- 1998-10-20 SG SG200203078A patent/SG105547A1/en unknown
- 1998-10-20 PL PL98340284A patent/PL194194B1/pl unknown
- 1998-10-20 CA CA002307175A patent/CA2307175C/en not_active Expired - Fee Related
- 1998-10-20 AT AT98967009T patent/ATE390486T1/de active
- 1998-10-20 ES ES05026205.4T patent/ES2496104T3/es not_active Expired - Lifetime
- 1998-10-21 ZA ZA989597A patent/ZA989597B/xx unknown
- 1998-10-22 AR ARP980105278A patent/AR020048A1/es unknown
- 1998-10-22 MY MYPI98004808A patent/MY136336A/en unknown
-
2000
- 2000-04-14 IS IS5449A patent/IS5449A/is unknown
- 2000-04-18 NO NO20002025A patent/NO20002025L/no not_active Application Discontinuation
- 2000-04-20 HR HR20000234A patent/HRP20000234A2/hr not_active Application Discontinuation
-
2002
- 2002-03-20 AR ARP020101003A patent/AR035786A2/es active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR035786A2 (es) | Variantes de factores de coagulacion dependientes de vitamina k y composiciones que los contienen | |
| JP2001520042A5 (es) | ||
| Sadler | Thrombomodulin structure and function | |
| ATE342962T1 (de) | Zusammensetzungen und verfahren für verbesserte zellkultur | |
| CO6230995A2 (es) | Antagonistas de activina-actrii y usos para aumentar los niveles de globulos rojas | |
| MXPA03002218A (es) | Peptidos antimicrobianos y metodos de uso. | |
| BRPI0014076B8 (pt) | benzamidas e inibidores correlatos do fator xa | |
| PT1548032E (pt) | Péptidos kdr e vacinas que os contêm | |
| AR000862A1 (es) | Variantes de una ó-amilasa madre, un metodo para producir la misma, una estructura de adn y un vector de expresion, una celula transformada por dichaestructura de adn y vector, un aditivo para detergente, composicion detergente, una composicion para lavado de ropa y una composicion para la eliminacion del | |
| PT883687E (pt) | Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes | |
| BR0108959A (pt) | Composições de poloxmero ou poloxamina melhoradas para distribuição de ácido nucléico | |
| TR200002179T2 (tr) | Kristalin teriparatid. | |
| DE3484616D1 (de) | Enzymwiderstandsfaehige immunomodulatorische peptide. | |
| IL142905A0 (en) | Functional antagonists of hedgehog activity | |
| BRPI0412799A (pt) | imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura | |
| WO2003012050A3 (en) | Mitochondrial genome replenishment | |
| ATE426028T1 (de) | Zellvolumenregulierte humane kinase h-sgk | |
| KR890000665A (ko) | 크링글 치환이 있는 돌연변이체 t-PA | |
| SE0301431D0 (sv) | Novel antimicrobial peptides | |
| Sánchez et al. | Isolation and characterization of two disintegrins inhibiting ADP-induced human platelet aggregation from the venom of Crotalus scutulatus scutulatus (Mohave Rattlesnake) | |
| AR035077A1 (es) | Polipeptidos de neublastina variante, proteinas de fusion, acidos nucleicos, vectores, celulas hospedadoras, metodos para producir dichos polipeptidos, dimeros, conjugados, composiciones farmaceuticas y uso de dichos polipeptidos en la preparacion de medicamentos | |
| AR042968A1 (es) | Anticuerpos de virus anti-dengue composiciones metodos y usos | |
| ES2113878T3 (es) | Proteina c hibrida. | |
| LTIP610A (en) | Inhibitors of cells proliferation, pharmaceutical composition and method for preparation of compounds | |
| IL152406A0 (en) | Anti-freeze proteins, their production and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |